Endocrine Pharmacology Practice Questions

Q: Which of the following is NOT a side effect of insulin?

Albuminuria. **Explanation:** **Albuminuria** is the correct answer because it is not a side effect of insulin; rather, it is a clinical marker of **Diabetic Nephropathy** (a complication of the disease itself). Insulin therapy is actually used to achieve glycemic control, which helps prevent or slow the progression of albuminuria. **Analysis of Options:** * **A. Edema:** Insulin causes renal sodium reabsorption in the distal tubules. In some patients, initiating insulin therapy leads to "Insulin Edema" due to salt and water retention. * **C. Hypoglycemia:** This is the **most common** and most serious side effect of insulin therapy, occurring due to an overdose, delayed meals, or excessive physical activity. * **D. Lipodystrophy:** This occurs at the site of injection. It can manifest as **Lipoatrophy** (immune-mediated loss of fat, rarer with human insulin) or **Lipohypertrophy** (fat accumulation due to the anabolic effects of insulin, often caused by failing to rotate injection sites). **High-Yield NEET-PG Pearls:** 1. **Weight Gain:** Insulin is an anabolic hormone; weight gain is a very common side effect. 2. **Hypokalemia:** Insulin shifts potassium into cells by activating the Na+/K+ ATPase pump. This is why it is used in the emergency management of hyperkalemia. 3. **Somogyi Effect:** Post-hypoglycemic hyperglycemia caused by a counter-regulatory hormonal surge (epinephrine, glucagon) in response to late-night hypoglycemia. 4. **Injection Sites:** Absorption is fastest in the abdomen, followed by the arms, thighs, and buttocks.

Q: Which of the following is NOT a testosterone inhibitor?

Sildenafil. ### Explanation The correct answer is **D. Sildenafil**. **Mechanism of Action (The "Why"):** Sildenafil is a **Phosphodiesterase-5 (PDE-5) inhibitor**. It works by preventing the degradation of cyclic Guanosine Monophosphate (cGMP) in the corpus cavernosum, leading to smooth muscle relaxation and increased blood flow. It is used to treat erectile dysfunction and pulmonary arterial hypertension. It does **not** interfere with the synthesis, metabolism, or receptor binding of testosterone. **Analysis of Incorrect Options:** * **A. Spironolactone:** A potassium-sparing diuretic that also acts as a weak **androgen receptor antagonist** and inhibits steroidogenesis. It is often used clinically to treat hirsutism in women due to these anti-androgenic effects. * **B. Flutamide:** A potent, non-steroidal **pure androgen receptor antagonist**. It competes with testosterone and dihydrotestosterone (DHT) for binding sites. It is primarily used in the management of prostate cancer. * **C. Finasteride:** A **5-alpha-reductase inhibitor**. It prevents the conversion of testosterone into its more potent metabolite, Dihydrotestosterone (DHT). It is used for Benign Prostatic Hyperplasia (BPH) and male pattern baldness. **High-Yield Clinical Pearls for NEET-PG:** * **Anti-androgen Classifications:** * *Receptor Antagonists:* Flutamide, Bicalutamide, Spironolactone, Cyproterone. * *5-α Reductase Inhibitors:* Finasteride (Type II), Dutasteride (Type I & II). * *GnRH Analogues (Continuous):* Leuprolide, Goserelin (initially cause a "flare," then suppress testosterone). * **Side Effect Note:** Spironolactone can cause **gynecomastia** in men due to its anti-androgenic activity. * **Sildenafil Contraindication:** Never co-administer with **nitrates**, as it can cause life-threatening hypotension.

Q: Which of the following is not a GnRH agonist?

Ganirelix. ### Explanation The correct answer is **Ganirelix**. **1. Understanding the Mechanism:** GnRH (Gonadotropin-Releasing Hormone) modulators are divided into two distinct classes based on their interaction with the GnRH receptor: * **GnRH Agonists:** These drugs initially cause a "flare" (surge in LH/FSH) followed by down-regulation and desensitization of receptors, leading to medical castration. * **GnRH Antagonists:** These drugs provide **immediate** suppression of gonadotropins by competitively blocking the GnRH receptor without any initial flare. **Ganirelix** (along with Cetrorelix and Degarelix) belongs to this class. **2. Analysis of Options:** * **Leuprolide (Option A):** A potent synthetic GnRH agonist used commonly in prostate cancer and endometriosis. * **Nafarelin (Option B):** A GnRH agonist typically administered as a nasal spray for central precocious puberty and endometriosis. * **Buserelin (Option D):** Another GnRH agonist used in the management of hormone-dependent tumors and IVF protocols. **3. NEET-PG High-Yield Pearls:** * **The "Relix" Rule:** Drugs ending in **"-relix"** (Ganirelix, Cetrorelix, Degarelix, Abarelix) are **Antagonists**. * **The "Relin" Rule:** Most drugs ending in **"-relin"** (Goserelin, Nafarelin, Buserelin, Triptorelin) are **Agonists** (Exception: Leuprolide). * **Clinical Use:** GnRH antagonists (Ganirelix) are preferred in IVF protocols to prevent premature LH surges because they act instantly and do not require the 7–10 day desensitization period needed by agonists. * **Side Effects:** Both classes cause symptoms of hypogonadism (hot flashes, decreased bone density). However, only agonists carry the risk of "tumor flare" in prostate cancer.

Q: Which drug, when taken by a patient, necessitates careful monitoring for hypoglycemia?

Chlorpropamide. **Explanation:** **Chlorpropamide** is a first-generation **Sulfonylurea** used in the management of Type 2 Diabetes Mellitus. Its primary mechanism of action involves stimulating insulin release from pancreatic beta cells by closing ATP-sensitive potassium channels. **Why Chlorpropamide causes hypoglycemia:** Among all sulfonylureas, Chlorpropamide has an exceptionally **long half-life (approx. 36 hours)** and is excreted unchanged by the kidneys. This prolonged duration of action significantly increases the risk of severe, prolonged hypoglycemia, especially in elderly patients or those with renal impairment. Therefore, patients on this drug require vigilant monitoring. **Analysis of Incorrect Options:** * **Furosemide (Loop Diuretic):** This drug is more likely to cause **hyperglycemia** (by inhibiting insulin release and causing hypokalemia) and electrolyte imbalances (hypokalemia, hyponatremia). * **Corticosteroids:** These are classic "diabetogenic" drugs. They promote gluconeogenesis and decrease peripheral glucose uptake, leading to **hyperglycemia** (Steroid-induced diabetes). * **Theophylline:** A methylxanthine used in asthma; in toxic doses, it typically causes **hyperglycemia** due to increased catecholamine release. **NEET-PG High-Yield Pearls:** 1. **Disulfiram-like reaction:** Chlorpropamide is notorious for causing flushing when taken with alcohol. 2. **SIADH:** Chlorpropamide can induce the Syndrome of Inappropriate Antidiuretic Hormone secretion, leading to dilutional hyponatremia. 3. **Drug of Choice for Hypoglycemia:** For sulfonylurea-induced hypoglycemia refractory to glucose, **Octreotide** (a somatostatin analogue) is used to suppress further insulin release.

Q: What is Pegvisomant used to treat?

Acromegaly. **Pegvisomant** is a genetically modified analogue of human growth hormone (GH) that acts as a highly selective **Growth Hormone Receptor Antagonist**. 1. **Why Acromegaly is correct:** Acromegaly is caused by excessive secretion of GH, usually due to a pituitary adenoma, leading to elevated Insulin-like Growth Factor-1 (IGF-1) levels [1]. Pegvisomant binds to the GH receptor but prevents the functional dimerization required for signal transduction. By blocking the peripheral action of GH, it effectively lowers serum IGF-1 levels, making it a potent treatment for patients who are resistant to or intolerant of somatostatin analogues (like Octreotide). 2. **Why the other options are incorrect:** * **Dwarfism:** This is caused by GH deficiency. Treatment requires **Somatropin** (recombinant GH) or **Mecasermin** (recombinant IGF-1), not an antagonist. * **Cretinism:** This refers to congenital hypothyroidism. It is treated with **Levothyroxine**. * **Protein Energy Malnutrition (PEM):** While GH levels may be high in PEM due to resistance, Pegvisomant has no therapeutic role here; management focuses on nutritional rehabilitation. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** It is a GH receptor antagonist (blocks the JAK2-STAT5 pathway). * **Monitoring:** Unlike Somatostatin analogues, Pegvisomant **does not shrink the pituitary tumor**. Therefore, serial MRI scans of the pituitary are mandatory. * **Side Effects:** Potential for liver enzyme elevation (monitor LFTs) and lipohypertrophy at the injection site. * **Biochemical Goal:** The primary goal of therapy is the normalization of **serum IGF-1 levels**, not GH levels (GH levels may actually rise during treatment due to loss of negative feedback).

Q: Bromocriptine inhibits which hormone?

Prolactin. **Explanation:** **Mechanism of Action:** Bromocriptine is a potent **Dopamine (D2) receptor agonist**. In the physiological regulation of the anterior pituitary, dopamine acts as the primary **Prolactin-Inhibiting Hormone (PIH)**. By stimulating D2 receptors on the lactotroph cells, Bromocriptine directly suppresses the synthesis and secretion of **Prolactin** [1, 2]. This makes it the first-line treatment for prolactinomas and hyperprolactinemia [2]. **Analysis of Options:** * **A. Prolactin (Correct):** As a dopamine agonist, Bromocriptine mimics the inhibitory effect of dopamine on prolactin release [2]. * **B. Vasopressin (Incorrect):** Vasopressin (ADH) is synthesized in the hypothalamus and released by the posterior pituitary. Its secretion is primarily regulated by plasma osmolality, not by D2 receptor agonists. * **C. Imipramine (Incorrect):** Imipramine is a Tricyclic Antidepressant (TCA). It is a drug, not a hormone, and its mechanism involves inhibiting the reuptake of Norepinephrine and Serotonin. * **D. Levodopa (Incorrect):** Levodopa is a precursor to dopamine used in Parkinson’s disease. While Bromocriptine and Levodopa are both used in Parkinsonism, Bromocriptine does not inhibit Levodopa; rather, they both aim to increase dopaminergic activity. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** While Bromocriptine is a classic answer, **Cabergoline** is now preferred for hyperprolactinemia due to its higher efficacy, longer half-life (twice-weekly dosing), and better side-effect profile [1]. * **Other Uses:** Bromocriptine is also used in **Acromegaly** (where it paradoxically decreases Growth Hormone) and **Parkinson’s Disease** [1]. * **Specific Side Effect:** Ergot-derived dopamine agonists like Bromocriptine are associated with **digital vasospasm** and **pulmonary/cardiac fibrosis** with long-term high-dose use.

Q: Which drug(s) can cause SIADH?

All of the above. The Syndrome of Inappropriate Antidiuretic Hormone (SIADH) is characterized by the excessive release of ADH (Vasopressin), leading to water retention, dilutional hyponatremia, and concentrated urine [1]. Several drugs can induce this condition by either stimulating the release of ADH from the posterior pituitary or by sensitizing the renal tubules to its effects. **Breakdown of Options:** * **Chlorpropamide (Option A):** This first-generation sulfonylurea is a classic cause of SIADH [1]. It acts by increasing the sensitivity of the V2 receptors in the renal collecting ducts to endogenous ADH and also stimulates ADH release [1]. * **Oxytocin (Option B):** Oxytocin is structurally very similar to ADH (differing by only two amino acids) [2]. When administered in high doses (e.g., for labor induction or postpartum hemorrhage), it exerts a "cross-reactivity" effect on V2 receptors, leading to potent antidiuretic activity and potential water intoxication [2]. * **Cyclophosphamide (Option C):** This alkylating cytotoxic agent can cause SIADH, particularly when administered intravenously. It is often given with aggressive hydration to prevent hemorrhagic cystitis; if SIADH occurs simultaneously, it significantly increases the risk of severe hyponatremia. **Clinical Pearls for NEET-PG:** * **Other High-Yield Drugs causing SIADH:** SSRIs (e.g., Fluoxetine), Carbamazepine [1], Vincristine, and Haloperidol. * **Treatment of Choice:** Fluid restriction is the first-line management [1]. For pharmacological intervention, **Vaptans** (Tolvaptan, Conivaptan) are used as ADH receptor antagonists [1]. * **Demeclocycline:** An older tetracycline used to treat chronic SIADH because it induces a state of nephrogenic diabetes insipidus [1].

Q: A 57-year-old lady presents with chief complaints of fatigue and a 5 kg weight gain in one month. She has a 10-year history of well-controlled hypothyroidism treated with L-thyroxine. Recently, she was started on an anti-arrhythmic drug for a cardiac condition, and her symptoms began after its initiation. What is the most likely anti-arrhythmic drug she was prescribed?

Amiodarone. **Explanation:** The patient is presenting with symptoms of **hypothyroidism** (fatigue, weight gain) despite being on stable L-thyroxine therapy. The temporal relationship between starting an anti-arrhythmic and the onset of symptoms points toward **Amiodarone**. **Why Amiodarone is the correct answer:** Amiodarone is a Class III anti-arrhythmic drug that is structurally unique because it contains approximately **37% iodine by weight**. It affects thyroid function through two primary mechanisms: 1. **Inhibition of 5’-deiodinase:** It blocks the peripheral conversion of T4 to the active T3. 2. **Wolff-Chaikoff Effect:** The high iodine content can lead to a transient or sustained inhibition of thyroid hormone synthesis. In patients with pre-existing thyroid disease (like this patient with a 10-year history), the thyroid may fail to "escape" this effect, leading to **Amiodarone-Induced Hypothyroidism (AIH)**. **Why other options are incorrect:** * **Lignocaine (Class Ib):** Primarily a sodium channel blocker used for ventricular arrhythmias; it has no effect on iodine metabolism or thyroid function. * **Procainamide (Class Ia):** Known for causing Drug-Induced Lupus Erythematosus (DILE), but it does not interfere with the thyroid axis. * **Verapamil (Class IV):** A calcium channel blocker used for supraventricular tachycardia; it does not impact thyroid hormone levels. **NEET-PG High-Yield Pearls:** * **Amiodarone-Induced Thyrotoxicosis (AIT):** Amiodarone can also cause hyperthyroidism via Type 1 (excess iodine substrate) or Type 2 (destructive thyroiditis). * **Half-life:** Amiodarone has an exceptionally long half-life (~weeks to months) due to its high lipid solubility. * **Monitoring:** Patients on Amiodarone require baseline and periodic **Thyroid Function Tests (TFTs)** and **Liver Function Tests (LFTs)**, along with monitoring for pulmonary fibrosis and corneal microdeposits.

Question 1

Which of the following is NOT a side effect of insulin?

Accepted Answer

Albuminuria

Answer

Edema

Answer

Hypoglycemia

Answer

Lipodystrophy

Question 2

Which of the following is NOT a testosterone inhibitor?

Accepted Answer

Sildenafil

Answer

Spironolactone

Answer

Flutamide

Answer

Finasteride

Question 3

Which of the following is not a GnRH agonist?

Accepted Answer

Ganirelix

Answer

Leuprolide

Answer

Nafarelin

Answer

Buserelin

Question 4

Which drug, when taken by a patient, necessitates careful monitoring for hypoglycemia?

Accepted Answer

Chlorpropamide

Answer

Furosemide

Answer

Corticosteroids

Answer

Theophylline

Question 5

What is Pegvisomant used to treat?

Accepted Answer

Acromegaly

Answer

Dwarfism

Answer

Cretinism

Answer

Protein energy malnutrition

Question 6

A drug primarily reduces the static component of urinary obstruction in benign prostatic hypertrophy and takes more than 3 months to exert its beneficial effect. Which of the following is this drug?

Accepted Answer

Finasteride

Answer

Tamsulosin

Answer

Terazosin

Answer

Amphetamine

Question 7

Bromocriptine inhibits which hormone?

Accepted Answer

Prolactin

Answer

Vasopressin

Answer

Imipramine

Answer

Levodopa

Question 8

Which drug(s) can cause SIADH?

Accepted Answer

All of the above

Answer

Chlorpropamide

Answer

Oxytocin

Answer

Cyclophosphamide

Question 9

A 57-year-old lady presents with chief complaints of fatigue and a 5 kg weight gain in one month. She has a 10-year history of well-controlled hypothyroidism treated with L-thyroxine. Recently, she was started on an anti-arrhythmic drug for a cardiac condition, and her symptoms began after its initiation. What is the most likely anti-arrhythmic drug she was prescribed?

Accepted Answer

Amiodarone

Answer

Lignocaine

Answer

Procainamide

Answer

Verapamil

Question 10

Which Dipeptidyl Peptidase-4 (DPP4) inhibitor requires dose reduction in both liver and kidney failure?

Accepted Answer

Vildagliptin

Answer

Linagliptin

Answer

Sitagliptin

Answer

Saxagliptin

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?